Docality.com Logo
 
Dr. Thomas  Pohlman  Md image

Dr. Thomas Pohlman Md

222 S Woods Mill Rd Suite 750
Chesterfield MO 63017
314 056-6600
Medical School: Washington University School Of Medicine - 1976
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: No
Participates In EHR: Yes
License #: R9417
NPI: 1760597629
Taxonomy Codes:
207RN0300X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Thomas Pohlman is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:90960 Description:Esrd srv 4 visits p mo 20+ Average Price:$566.00 Average Price Allowed
By Medicare:
$279.42
HCPCS Code:90961 Description:Esrd srv 2-3 vsts p mo 20+ Average Price:$465.00 Average Price Allowed
By Medicare:
$232.51
HCPCS Code:99223 Description:Initial hospital care Average Price:$386.00 Average Price Allowed
By Medicare:
$194.06
HCPCS Code:90962 Description:Esrd serv 1 visit p mo 20+ Average Price:$348.00 Average Price Allowed
By Medicare:
$176.80
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$202.00 Average Price Allowed
By Medicare:
$102.58
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$198.00 Average Price Allowed
By Medicare:
$99.33
HCPCS Code:90935 Description:Hemodialysis one evaluation Average Price:$149.00 Average Price Allowed
By Medicare:
$72.30
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$138.00 Average Price Allowed
By Medicare:
$69.24
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$46.00 Average Price Allowed
By Medicare:
$23.54
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$46.00 Average Price Allowed
By Medicare:
$23.54
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$35.00 Average Price Allowed
By Medicare:
$14.03
HCPCS Code:J0885 Description:Epoetin alfa, non-esrd Average Price:$20.00 Average Price Allowed
By Medicare:
$9.73
HCPCS Code:81000 Description:Urinalysis nonauto w/scope Average Price:$9.07 Average Price Allowed
By Medicare:
$4.48

HCPCS Code Definitions

96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
90935
Hemodialysis procedure with single evaluation by a physician or other qualified health care professional
90962
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 1 face-to-face visit by a physician or other qualified health care professional per month
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
90961
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month
90960
End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 4 or more face-to-face visits by a physician or other qualified health care professional per month
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
G0008
Administration of influenza virus vaccine
J0885
Injection, epoetin alfa, (for non-esrd use), 1000 units
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1528086659
Endocrinology
3,655
1821055492
Cardiovascular Disease (Cardiology)
2,517
1871526863
Diagnostic Radiology
2,354
1952323875
Diagnostic Radiology
2,297
1265450944
Diagnostic Radiology
2,167
1528086931
Diagnostic Radiology
1,868
1861449753
Internal Medicine
1,816
1326269648
Vascular Surgery
1,719
1902839970
Diagnostic Radiology
1,668
1255365581
Endocrinology
1,587
*These referrals represent the top 10 that Dr. Pohlman has made to other doctors

Publications

CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media. - Journal of blood transfusion
This paper reviews the application of tranexamic acid, an antifibrinolytic, to trauma. CRASH-2, a large randomized controlled trial, was the first to show a reduction in mortality and recommend tranexamic acid use in bleeding trauma patients. However, this paper was not without controversy. Its patient recruitment, methodology, and conductance in moderate-to-low income countries cast doubt on its ability to be applied to trauma protocols in countries with mature trauma networks. In addition to traditional vetting in scientific, peer-reviewed journals, CRASH-2 came about at a time when advances in communication technology allowed debate and influence to be leveraged in new forms, specifically through the use of multimedia campaigns, social media, and Internet blogs. This paper presents a comprehensive view of tranexamic acid utilization in trauma from peer-reviewed evidence to novel multimedia influences.
Synergistic effect of major histocompatibility complex class I-related chain a and human leukocyte antigen-DPB1 mismatches in association with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation. - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
The clinical relevance of mismatches at the MHC class I-related chain A (MICA) in hematopoietic stem cell transplantation (HSCT) remains unclear. We investigated the association of MICA donor/recipient mismatch and whether there is an interaction between these and HLA-DPB1 mismatch on clinical outcomes after unrelated donor HSCT. Our study included 227 patients who underwent unrelated donor allogeneic HSCT at our institution between 2000 and 2010. Among these, 177 (78%) received HSCT from a 10/10 HLA-matched donor. MICA genotyping was performed using commercially available kits. In univariable analysis, the risk of grade II to IV acute graft-versus-host disease (GVHD) was greater for patients with MICA mismatch (hazard ratio [HR], 1.73; P = .02) than for those with HLA-DPB1 mismatch (HR, 1.62; P = .07). When MICA and HLA-DPB1 were assessed simultaneously, patients mismatched at both loci had the greatest risk (HR, 2.51; P < .01) and those mismatched at only 1 locus had somewhat greater risk (HR, 1.53; P = .12) than patients matched at both loci; this remained significant in multivariable analysis. The 100-day incidence was 66%, 45%, and 31%, respectively (P = .03). Results were similar for grade III and IV acute GVHD, with 100-day incidence 34%, 16%, and 8% (P = .01). These results are clinically pertinent to donor selection strategies and indicate that patients with mismatch at both MICA and HLA-DPB1 are at increased risk for acute GVHD.Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation. - Bone marrow transplantation
Achievement of complete donor chimerism (CDC) after allogeneic nonmyeloablative hematopoietic stem cell transplantation (NMHSCT) is important for preventing graft rejection and for generating a graft-vs-malignancy effect. The alloreactivity of NK cells and some T-cell subsets is mediated through the interaction of their killer immunoglobulin-like receptors (KIRs) with target cell HLA/KIR ligands. The influence of KIR matching on the achievement of T-cell CDC after NMHSCT has not been previously described. We analyzed 31 patients undergoing T-cell replete related donor NMHSCT following fludarabine and 200 cGy TBI. Recipient inhibitory KIR genotype and donor HLA/KIR ligand matches were used to generate an inhibitory KIR score from 1 to 4 based upon the potential number of recipient inhibitory KIRs that could be engaged with donor HLA/KIR ligands. Patients with a score of 1 were less likely to achieve T-cell CDC (P=0.016) and more likely to develop graft rejection (P=0.011) than those with scores greater than 1. Thus, patients with lower inhibitory KIR scores may have more active anti-donor immune effector cells that may reduce donor chimerism. Conversely, patients with greater inhibitory KIR scores may have less active NK cell and T-cell populations, which may make them more likely to achieve CDC.
Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction? - Bone marrow transplantation
Experience with autologous bone marrow transplantation (ABMT) in patients with impaired left ventricular ejection fraction (LVEF) or heart failure (HF) is limited. We identified 308 consecutive patients who underwent ABMT for Hodgkin's or non-Hodgkin's lymphoma at our institution (1996-2003). Patient characteristics, clinical course and overall survival were compared between patients with preserved ( > or = 50%) or impaired ( < 50%) LVEF. Of the 308 patients identified, 20 had baseline impaired LVEF (four with LVEF < or = 40%, all NYHA class I-II HF). None of the patients with post-ABMT echocardiogram had worsened LVEF (n = 7). Among the 20 patients with impaired LVEF, four patients had reversible cardiac complications post-ABMT (including worsening HF). The two deaths observed in the impaired LVEF group were both due to noncardiac causes. The 5-year survival was similar between patients with preserved and impaired LVEF (P = 0.43). Careful selection of patients with stable, mild-to-moderate HF and impaired LVEF for ABMT can achieve similar long-term survival. As medical care for HF and ABMT improves, the exclusion criteria for ABMT with regard to HF and impaired LVEF should be re-examined.

Map & Directions

222 S Woods Mill Rd Suite 750 Chesterfield, MO 63017
View Directions In Google Maps

Nearby Doctors

232 S Woods Mill Rd St Lukes Hospital Radiology
Chesterfield, MO 63017
314 341-1500
232 S Woods Mill Rd
Chesterfield, MO 63017
314 056-6917
226 S Woods Mill Rd Suite 49 W
Chesterfield, MO 63017
314 341-1211
232 S Woods Mill Rd 330 East
Chesterfield, MO 63017
314 056-6737
14378 Woodlake Dr
Chesterfield, MO 63017
314 767-7750
603 Claymont Estates Dr
Chesterfield, MO 63017
636 567-7878
2319 Westpar Dr
Chesterfield, MO 63017
636 075-5800
226 S Woods Mill Rd Suite 55 West
Chesterfield, MO 63017
314 694-4440
130 Hilltown Village Ctr
Chesterfield, MO 63017
636 323-3311